The act­ing gen­er­al coun­sel at HHS, Bob Fos­ter, is no longer at the agency.

When End­points Newscon­tact­ed Fos­ter through his gov­ern­ment email, it re­ceived...

Top phar­ma­ceu­ti­cal trade groups say the FDA will have a ded­i­cat­ed pool of mon­ey to re­plen­ish its sta­ble of re­view­ers as part of the new...

The phar­ma in­dus­try is yet again tak­ing the gov­ern­ment to court over its lat­est ef­fort to con­trol US drug prices.

Last week, the Trump ad­min­is­tra­tion...

There is some good news in the world of an­tibi­otics.

No­var­tis qui­et­ly snagged sup­ple­men­tal FDA ap­proval for its drug Lam­prene over the sum­mer, tran­si­tion­ing a decades-old...

Ul­tragenyx Phar­ma­ceu­ti­cal is sell­ing a pri­or­i­ty re­view vouch­er to an undis­closed buy­er for $210 mil­lion, mark­ing one of the rich­est sales of the speedy-ap­proval...

Japan­ese phar­ma Asahi Ka­sei Ther­a­peu­tics has snagged FDA ap­proval for a her­pes treat­ment that it ac­quired ear­ly this year in an al­most $1 bil­lion deal...